Our proprietary CleanCap technology is the fastest and easiest way to produce a 5’ Cap 1 mRNA with 95% efficiency, offering a modern alternative to enzymatic capping. With GMP grade now available, CleanCap reagents are an immediate solution for swiftly scaling from clinical to commercial therapeutics production.
TriLink’s high-purity, GMP-grade modified nucleoside triphosphates optimize and enhance mRNA performance to promote robust protein expression. From research use through clinical and commercial manufacturing, our N1-Methylpseudouridine-5’-Triphosphate is tried and trusted by global vaccine and therapeutics programs and are ready to scale to your unique production needs.
Our state-of-the-art Current Good Manufacturing Practice (cGMP) facility operates at the highest quality standards. Covering 118,000 sq. ft, the facility contains multiple specialized manufacturing suites and support labs, ensuring success across a wide variety of synthesis scales.
Ready to elevate your mRNA therapeutics process? Talk to our team about what may be the best option for you.
Get started today.